Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Trial Parameters
Brief Summary
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.
Eligibility Criteria
Inclusion Criteria: * Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group); * Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group). Exclusion Criteria: * Severe chronic kidney disease (stage 4-5); * Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease; * Other non-neuroendocrine malignancies.